Trial Profile
A Three-part, Randomized Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy, Young Subjects and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs BC 007 (Primary)
- Indications Chronic fatigue syndrome; Dilated cardiomyopathy
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Berlin Cures
- 28 Mar 2020 Results published in the Clinical Drug Investigation
- 17 Jul 2018 Status changed from recruiting to completed.
- 26 Feb 2018 According to a Berlin Cures media release, data of 68 patients from this trial will be presented at the annual scientific session of American College of Cardiology (2018).